(Q41935347)

English

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

scientific article published on 26 June 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation (English)

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

author name string

Stephen A Beers

1

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Claude H T Chan

2

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Sonya James

3

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Ruth R French

4

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Kathrine E Attfield

5

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Claire M Brennan

6

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Anupama Ahuja

7

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Mark J Shlomchik

8

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

Martin J Glennie

10

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

language of work or name

0 references

publication date

26 June 2008

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

112

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

10

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

4170-4177

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582008

5 June 2018

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582008

5 June 2018

The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582008

5 June 2018

The biology of CD20 and its potential as a target for mAb therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582008

5 June 2018

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582008

5 June 2018

Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582008

5 June 2018

Complement activation determines the therapeutic activity of rituximab in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582008

5 June 2018

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582008

5 June 2018

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582008

5 June 2018

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582008

18 August 2018

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2582008

2 December 2018

Recombinant mouse monoclonal antibodies with single amino acid substitutions affecting Clq and high affinity Fc receptor binding have identical serum half-lives in the BALB/c mouse

1 reference

https://pubmed.ncbi.nlm.nih.gov/18583569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/18583569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The binding site for C1q on IgG

1 reference

https://pubmed.ncbi.nlm.nih.gov/18583569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18583569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18583569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

1 reference

https://pubmed.ncbi.nlm.nih.gov/18583569

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2008-04-149161

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41935347&oldid=2119125164"